S. Ghabri

发表

Nifurtimox-efl ornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis : a multicentre , randomised , phase III , non-inferiority trial

V. Kande, E. Torreele, M. Ilunga, 2009 .

Could or Should We Use MCDA in the French HTA Process?

S. Ghabri, Benoît Le Maux, J. Josselin, 2019, PharmacoEconomics.

Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review

P. Bousquet, S. Ghabri, Elsa Bouée-Benhamiche, 2020, Applied Health Economics and Health Policy.

Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health

F. Hamers, S. Ghabri, J. Josselin, 2016, PharmacoEconomics.

In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness

Salah Ghabri, Johannes Blum, S. Blesson, 2012, PLoS neglected tropical diseases.

Three Drug Combinations for Late-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in Uganda

F. Checchi, M. Balasegaram, P. Piola, 2006, PLoS clinical trials.

The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges

J. Mauskopf, S. Ghabri, 2018, The European Journal of Health Economics.

Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda

L. Pinoges, D. Caugant, P. Guérin, 2008, PLoS neglected tropical diseases.

Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.

G. Priotto, S. Kasparian, D. Ngouama, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The moisturizing effect of a wheat extract food supplement on women’s skin: a randomized, double‐blind placebo‐controlled trial

S. Ghabri, S. Guillou, I. Lamour, 2011, International journal of cosmetic science.

Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report.

J. Severens, L. Vale, T. Mathes, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.

Elisabeth Fenwick, Lotte Steuten, Saskia Knies, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs

S. Ghabri, L. Lam, F. Bocquet, 2020, PharmacoEconomics.

Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis

S. Paisley, M. Stevenson, A. Binard, 2019, International Journal of Technology Assessment in Health Care.

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

Salah Ghabri, Els Torreele, Sara Ghorashian, 2009, The Lancet.

Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries

E. Heintz, F. Hamers, T. Davidson, 2015, PharmacoEconomics.

Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France.

A. Binard, J. Caro, Y. Pers, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.

Elisabeth Fenwick, Lotte Steuten, Saskia Knies, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Reproducibility and sensitivity to change of various methods to measure joint space width in osteoarthritis of the hip: a double reading of three different radiographic views taken with a three-year interval

T. Spector, M. Dougados, E. Vignon, 2005, Arthritis research & therapy.

Four Aspects Affecting Health Economic Decision Models and Their Validation

T. Feenstra, G. van Voorn, S. Ghabri, 2021, PharmacoEconomics.

Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?

Salah Ghabri, Matt Stevenson, Jörgen Möller, 2018, PharmacoEconomics.

Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines

Salah Ghabri, Jean-Michel Josselin, Irina Cleemput, 2018, PharmacoEconomics.

Reproducibility and sensitivity to change of various methods of joint space width (JSW) measurements in osteoarthritis of the hip (OAH). A double reading of three different radiographic views taken within a 3-year time-interval.

T. Spector, M. Dougados, E. Vignon, 2005 .

The moisturizing effect of a wheat extract food supplement on women’s skin: a randomized, double‐blind placebo‐controlled trial

S. Ghabri, S. Guillou, I. Lamour, 2011, International journal of cosmetic science.